| http://purl.uniprot.org/citations/24956244 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/24956244 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/24956244 | http://www.w3.org/2000/01/rdf-schema#comment | "We describe a 64-year-old male of Indian descent with a history of atrial fibrillation who was started on warfarin after hospital admission for acute stroke. He received genotype-guided warfarin dosing as per the standard-of-care at our hospital, with daily dose recommendations provided by the pharmacogenetics service. Genotyping revealed the rare CYP2C9*1/*14 genotype and warfarin insensitive VKORC1 -1639GG and CYP4F2 433Met/Met genotypes. The patient received an initial warfarin loading dose of 4 mg for 2 days, followed by 2-3 mg/day for the following 11 days. He reached a therapeutic international normalized ratio on day 5, which was maintained over the following week. This report adds to the limited data of the effects of the CYP2C9*14 allele on warfarin dose requirements."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.org/dc/terms/identifier | "doi:10.2217/pgs.14.47"xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.org/dc/terms/identifier | "doi:10.2217/pgs.14.47"xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Lee Y.M."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Lee Y.M."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Cavallari L.H."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Cavallari L.H."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Drozda K."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Drozda K."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Eggen J."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Eggen J."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Nutescu E.A."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Nutescu E.A."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Soni V."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/author | "Soni V."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/date | "2014"xsd:gYear |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/date | "2014"xsd:gYear |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/name | "Pharmacogenomics"xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/name | "Pharmacogenomics"xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/pages | "909-914"xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/pages | "909-914"xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/title | "Warfarin dose requirements in a patient with the CYP2C9*14 allele."xsd:string |
| http://purl.uniprot.org/citations/24956244 | http://purl.uniprot.org/core/title | "Warfarin dose requirements in a patient with the CYP2C9*14 allele."xsd:string |